Bain Capital has agreed to acquire Mitsubishi Chemical Group's pharmaceutical business for more than $3 billion, a deal that would allow the Japanese company to focus on its key chemical businesses.

At this year’s Davos it was impossible to escape AI. Central to these discussions was the shift toward “agentic AI”, which ...

Korean Air anticipates uncertainties in the business environment this year due to shifts in the global political landscape, ...

Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Bain Capital has agreed to acquire Tanabe Pharma, the pharma arm of Mitsubishi Chemical Group Corporation. The deal puts Tanabe Pharma at a valuation of about $3.3 billion. Founded in 1678, Tanabe ...

Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.

Keith Largay joins Bain Capital from JLL, where he spent 14 years and most recently served as co-head of its Chicago office.

TOKYO -- Japan's Mitsubishi Chemical Group announced on Friday the agreed sale of its pharmaceutical subsidiary, Mitsubishi Tanabe Pharma, to U.S. investment fund Bain Capital for approximately 510 ...

Banks are expecting increased M&A activity across the financial sector, but are concerned about acquisition by credit unions ...